Evidence map›Paper›PMID 29434975›Full record

ArticleOncology letters2018

Validation of the novel susceptibility loci for prostate cancer in a Chinese population.

Yishuo Wu, Haitao Chen, Ying Ji, Rong Na, Zengnan Mo, Dingwei Ye, Meilin Wang, Jun Qi, Xiaoling Lin, Qiang Ding and 4 more

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 2 countries.

Yishuo WuDepartment of Urology, Huashan Hospital, Fudan University, Shanghai 200000, P.R. China.
Haitao ChenCenter for Genomic Translational Medicine and Prevention, School of Public Health, Fudan University, Shanghai 200000, P.R. China.
Ying JiDepartment of Urology, Huashan Hospital, Fudan University, Shanghai 200000, P.R. China.
Rong NaDepartment of Urology, Huashan Hospital, Fudan University, Shanghai 200000, P.R. China.
Zengnan MoCenter for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi 530000, P.R. China.
Dingwei YeDepartment of Urology, Shanghai Cancer Center, Fudan University, Shanghai 200000, P.R. China.
Meilin WangDepartment of Molecular and Genetic Toxicology, The Key Laboratory of Modern Toxicology of The Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 210000, P.R. China.
Jun QiDepartment of Urology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200000, P.R. China.
Xiaoling LinUrology Research Center, Fudan University, Shanghai 200000, P.R. China.
Qiang DingDepartment of Urology, Huashan Hospital, Fudan University, Shanghai 200000, P.R. China.
Jianfeng XuUrology Research Center, Fudan University, Shanghai 200000, P.R. China.
S Lilly ZhengProgram for Personalized Cancer Care, NorthShore University Health System, Evanston, IL 60201, USA.
Yinghao SunDepartment of Urology, Changhai Hospital, The Second Military Medical University, Shanghai 200000, P.R. China.
Wei MengDepartment of Epidemiology, School of Public Health, Fudan University, Shanghai 200000, P.R. China.
Fudan University · CNChanghai Hospital · CNFudan University Shanghai Cancer Center · CNGuangxi Medical University · CNHuashan Hospital · CNNanjing Medical University · CNNorthShore University HealthSystem · USXinHua Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study evaluated 23 newly identified susceptibility loci for prostate cancer (PCa) in a Chinese population and assessed whether any validated loci were associated with the genetic risk score (GRS) of PCa in a Chinese population. A total of 1,417 patients with PCa and 1,008 controls were recruited in the present study. The association of each single nucleotide polymorphism (SNP) with PCa risk and PCa aggressiveness was analyzed. The predictive ability of two GRSs based on 30 SNPs (GRS30) and the 9 most significant SNPs (GRS9) in the Chinese population were also compared. Among the 19 SNPs evaluated, 1 SNP (rs7153648 at 14q23) was associated with PCa risk [odds ratio (OR)=1.206, P<0.05)] and 1 SNP (rs636291 at 1p23) was associated with PCa aggressiveness (OR=1.123, P<0.05). GRS30 and GRS9 were significantly increased in patients with PCa compared with that among non-PCa controls. The areas under receiver operating characteristic curves of GRS9 and GRS 30 were similar (0.792 for GRS9 vs. 0.7994 for GRS30, P=0.138). To conclude, among the 19 SNPs evaluated, only 1 SNP was associated with PCa risk in the Chinese population. SNPs that were weakly associated with PCa were unlikely to improve the predictive ability of existing GRS in the Chinese population.

Indexed as

Chinesegenetic risk scoreprostate cancersingle nucleotide polymorphisms

Identifiers

PMID29434975
PMCPMC5777361
OpenAlexW2774240559

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.